Organon/$OGN
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Organon
Organon & Co is a science-based pharmaceutical company that develops and delivers health solutions through a portfolio of prescription therapies within women's health, biosimilars, and established brands. The Company's operations include the following product portfolio: Women's health, Biosimilars and Established medicines. Geographically, it derives a majority of its revenue from Europe and Canada followed by the United States and then Asia Pacific and Japan. The company generates the majority of its revenue from the Established Brands product portfolio.
Ticker
$OGN
Sector
Primary listing
NYSE
Employees
10,000
Headquarters
Website
Organon Metrics
BasicAdvanced
$2.8B
3.96
$2.69
0.56
$0.60
0.75%
Price and volume
Market cap
$2.8B
Beta
0.56
52-week high
$20.44
52-week low
$8.01
Average daily volume
4.4M
Dividend rate
$0.60
Financial strength
Current ratio
1.652
Quick ratio
0.755
Long term debt to equity
1,197.954
Total debt to equity
1,652.399
Dividend payout ratio (TTM)
32.71%
Interest coverage (TTM)
2.51%
Profitability
EBITDA (TTM)
1,677
Gross margin (TTM)
56.47%
Net profit margin (TTM)
11.14%
Operating margin (TTM)
21.62%
Effective tax rate (TTM)
-5.11%
Revenue per employee (TTM)
$630,000
Management effectiveness
Return on assets (TTM)
6.62%
Return on equity (TTM)
159.64%
Valuation
Price to earnings (TTM)
3.962
Price to revenue (TTM)
0.438
Price to book
3.78
Price to tangible book (TTM)
-0.52
Price to free cash flow (TTM)
5.706
Free cash flow yield (TTM)
17.52%
Free cash flow per share (TTM)
1.866
Dividend yield (TTM)
5.63%
Forward dividend yield
0.75%
Growth
Revenue change (TTM)
-1.02%
Earnings per share change (TTM)
-30.66%
3-year revenue growth (CAGR)
-0.39%
3-year earnings per share growth (CAGR)
-14.77%
3-year dividend per share growth (CAGR)
-8.43%
What the Analysts think about Organon
Analyst ratings (Buy, Hold, Sell) for Organon stock.
Bulls say / Bears say
Organon posted Q2 revenue of $1.594 billion, surpassing the $1.55 billion consensus, and raised its full-year 2025 revenue guidance to $6.275–$6.375 billion, showing strong, resilient demand (Reuters).
The company repaid $345 million in long-term debt in Q2, moving closer to its sub-4.0× net leverage goal for year-end and improving its financial flexibility (Business Wire).
Core Women's Health sales increased 10% in Q1 (12% ex-FX) and 3% in Q2 (2% ex-FX), led by double-digit growth in Nexplanon and fertility products, highlighting strength in its main growth area (Business Wire) (Business Wire).
Established Brands revenue declined 11% in Q1 (8% ex-FX) and 3% in Q2 (4% ex-FX) due to loss of exclusivity of Atozet and pricing pressures in Europe and Asia, weighing on overall top-line growth (Business Wire) (Business Wire).
The 93% dividend cut to $0.02 per share in Q1 reduced the dividend yield to under 1%, detracting from the stock's appeal for income-focused investors and indicating that cash flow is being redirected toward debt repayments (Investing.com).
Organon’s net leverage remains above the 4.0× target, with management aiming to reduce it to below 4.0× only by year-end, exposing the company to ongoing refinancing risk and higher interest expenses in the meantime (Reuters).
Data summarised monthly by Lightyear AI. Last updated on 1 Sept 2025.
Organon Financial Performance
Revenues and expenses
Organon Earnings Performance
Company profitability
Organon News
AllArticlesVideos
US Food and Drug Administration (FDA) Approves Henlius and Organon's BILDYOS® (denosumab-nxxp) and BILPREVDA® (denosumab-nxxp), Biosimilars to PROLIA (denosumab) and XGEVA (denosumab), Respectively
Business Wire2 weeks ago
Organon Reports Results for the Second Quarter Ended June 30, 2025
Business Wire1 month ago
FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Organon
Business Wire2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Organon stock?
Organon (OGN) has a market cap of $2.8B as of September 13, 2025.
What is the P/E ratio for Organon stock?
The price to earnings (P/E) ratio for Organon (OGN) stock is 3.96 as of September 13, 2025.
Does Organon stock pay dividends?
Yes, the Organon (OGN) stock pays dividends to shareholders. As of September 13, 2025, the dividend rate is $0.6 and the yield is 0.75%. Organon has a payout ratio of 32.71% on a trailing twelve-month basis.
When is the next Organon dividend payment date?
The next Organon (OGN) dividend payment date is unconfirmed.
What is the beta indicator for Organon?
Organon (OGN) has a beta rating of 0.56. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.